Bepirovirsen Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Bepirovirsen comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hepatitis B. Most recent publication: A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants., Clin Pharmacol Drug Dev, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants.
    Youssef AS, Shah P, Hu M, et al. · Clin Pharmacol Drug Dev · 2026
    PubMed: PMID 41085094 · NCT06058390 · Hepatitis B
  2. Antisense oligonucleotides as drugs with both direct and indirect antiviral actions.
    Hong J, Rajwanshi VK · Antiviral Res · 2025
    PubMed: PMID 40562220 · NCT06537414 (B-UNITED) · Hepatitis B

Publications by year

2025–2026: 2 publications.

2025
1
2026
1

Publications by indication

Hepatitis B (2)

  • A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants.
    Clin Pharmacol Drug Dev · 2026 · PMID 41085094 · NCT06058390
  • Antisense oligonucleotides as drugs with both direct and indirect antiviral actions.
    Antiviral Res · 2025 · PMID 40562220 · NCT06537414

Publications by journal

  • Clin Pharmacol Drug Dev1 paper
  • Antiviral Res1 paper

All Bepirovirsen publications (2)

2026 (1 paper)

  1. A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants.
    Youssef AS, Shah P, Hu M, et al. · Clin Pharmacol Drug Dev · 2026 · Derived
    PubMed: PMID 41085094 · NCT06058390 · Hepatitis B

2025 (1 paper)

  1. Antisense oligonucleotides as drugs with both direct and indirect antiviral actions.
    Hong J, Rajwanshi VK · Antiviral Res · 2025 · Derived
    PubMed: PMID 40562220 · NCT06537414 (B-UNITED) · Hepatitis B

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Wed, 27 May 2026 18:57:18 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).